Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.

Gentian Diagnostics ASA

Gentian develops and produces diagnostic tests for clinical chemistry, focusing on improving efficiency for laboratories and patients.

Gentian

Gentian Diagnostics – a global medical diagnostics company – develops and manufactures high quality, in vitro diagnostic (IVD) reagents for a wide range of clinical chemistry analysers. Our product lines of laboratory tests, for diverse medical conditions, improve accuracy and provide faster results, for both human and veterinary healthcare. 

Gentian Diagnostics serves the global market for human and veterinary medical diagnostic tests via our OEM partners and key distributors. The Gentian HQ and production facility is in Moss, Norway. We also have a representative office in China and the distribution subsidiaries: Gentian USA, Inc. and Gentian Diagnostics AB (Sweden). 

Our interdisciplinary and international teams work on global solutions to ensure #DiagnosticEfficiency.   

Gentian'S turbidimetric immunoassays: GCAL® PLASMA AND SERUM CALPROTECTIN – CYSTATIN C – CANINE CRP- RETINOL-BINDING PROTEIN - SARS-CoV-2 TOTAL ANTIBODY

Connect with us:
Web: www.gentian.com
E-mail: marketing@gentian.com
Facebook: facebook.com/GentianDiagnostics
Twitter: twitter.com/GentianDiagnost
Twitter: twitter.com/Cystatin_C
Instagram: instagram.com/gentiandiagnostics/

Gentian Diagnostics 

#DiagnosticEfficiency👩🏼‍🔬 Exciting #NTproBNP news from Gentian at #ADLM2024 last week! 🚀 Our poster, "Development and Diagnostic Utility of Immunoturbidimetric NT-proBNP Assay," showcased our innovative approach targeting non-glycosylated regions of the molecule to measure total NT-proBNP accurately. 

Unlike most commercial tests that underestimate NT-proBNP levels, our prototype demonstrated excellent analytical performance, confirming its potential to revolutionise NT-proBNP measurements and enhance accessibility on #clinicalchemistry platforms. Read more👉https://lnkd.in/dU42JGiv

We are here! Excited for day 1 at #ADLM2024! Come by booth #3201 say hello #diagnosticefficiency

At #ADLM2024 and interested to learn more about the biomarker #calprotectin (S100A8/A9 protein)?  Circulating calprotectin has been shown to be involved in various inflammatory conditions. Discover its potential at our poster B-068: "Plasma Calprotectin as an Index of Draining Tunnel Formation in Hidradenitis Suppurativa (HS)," where we present calprotectin as a biomarker for assessing disease severity in HS patients.

Learn more about circulating calprotectin and HS 👉 https://lnkd.in/dBnnAHmS

Don’t miss the opportunity to meet Gentian’s CSO, Aleksandra Havelka Havelka, and Global Product Manager, Elin Godager, at the poster session on Wednesday, July 31, from 1:30 to 2:30 p.m., or visit us at #booth3201 to learn more about this novel biomarker.

#ADLM2024 Gentian's turbidimetric #NTproBNP assay, now in the verification phase, will uniquely target non-glycosylated areas of the molecule, and therefore measure the total amount of NT-proBNP, unlike most current commercial tests which bind to glycosylated regions of NT-proBNP molecule. 

Learn more about Nt-proBNP and the assay development👉 https://lnkd.in/ddQxPZ4y

At #ADLM in Chicago? Don't miss the opportunity to delve deeper into this ground-breaking development and engage with us at the poster session tomorrow Tuesday 30 July from 1:30 to 2:30 p.m.: A-010. “Development and diagnostic utility of immunoturbidimetric NT-proBNP assay based on antibodies targeting glycosylation-free regions of NT-proBNP”.

Meet Gentian’s CSO, Aleksandra Mandic Havelka , and Global Product Manager, Elin Godager, at the poster session or visit us at #booth3201 to learn more about #DiagnosticEfficiency👩🏼‍🔬 and Gentian's products

The Gentian team has a great time at #ADLM2024! see you at booth #3201 to discuss #diagnosticefficiency and learn more about our assays and #DiagnosticEfficiency👩🏼‍🔬 #CystatinC

#DiagnosticEfficiency👩🏼‍🔬 Going to #ADLM2024? Learn more about Gentian's turbidimetric Retinol-Binding Protein #RBP at booth #3201 See you next week! Read more about the assay👉https://lnkd.in/d4NADTcp

Metric
Company Name	Gentian Diagnostics ASA
Symbol	GENT
MSH ID	COM:GENTIAN
Market	STOCKS
Sector	Healthcare
Industry	Medical - Devices
Country	NO
Stage
Employee Count	58
Website	gentian.com
LinkedIn	gentian-technology-as
Founders

Metric
Market Cap	77.51M
Enterprise Value
Monthly Web Traffic	163
Web Traffic Growth	-0.82
Valuation
Raised Capital

Metric
Revenue	12.13M
Revenue (LTM)
Revenue (NTM)
Gross Profit	5.28M
EBITDA	-351.87K
Operating Income	-1.21M
Net Income	-929.43K
EPS	-0.06
Diluted EPS	-0.06
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.49
Operating Profit Margin	0.01
EBITDA Margin	-0.03
Net Profit Margin	-0.01
Return on Equity	-0.01
Return on Assets	-0.01
Return on Capital Employed	0.01

GENT

COM:GENTIAN

Gentian

Last Close

41.00

22/11 15:27

Market Cap

863.65M

Beta: -

Volume Today

4.42K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-110.86
P/B Ratio	4.16
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.36
EV Multiple	92.34

Metric
Days Sales Outstanding	68.80
Days Payables Outstanding	135.81
Days Inventory Outstanding	200.64
Operating Cycle	258.97
Cash Conversion Cycle	153.63
Asset Turnover	0.79

Metric
Operating Cash Flow	1.39M
Free Cash Flow	983.90K
Cash Flow to Debt	2.39
Operating Cash Flow/Sales	0.15
Free Cash Flow Yield	-0.02

Metric
Cash & Equivalents	7.86M
Accounts Receivable	-103.92K
Inventory	3.33M
Goodwill
Debt to Capitalization	0.08
Debt to Assets	0.05
Current Ratio	6.32
Quick Ratio	4.83

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.03
R&D to Revenue
SG&A to Revenue